Showing 4861-4870 of 8165 results for "".
- Get to Know the Dermatology Hall of Fame's 2019 Inaugural Class of Inducteeshttps://practicaldermatology.com/news/meet-the-dermatology-hall-of-fame-2019-inaugural-class-of-inductees/2459984/The 10 individuals inducted into the Dermatology Hall of Fame’s 2019 Inaugural Class are: Albert Bernard Ackerman, M.D., the author of “Histologic Diagnosis of Inflammatory Skin Diseases” and recipient of the American Academy of Dermatology’s Master Dermatologist
- Cheryl Deguara Returns to Sciton in New Rolehttps://practicaldermatology.com/news/cheryl-deguara-returns-to-sciton-in-new-role/2459985/Cheryl Deguara, PhD is the new Senior Director, Product Innovation & Clinical Research at Sciton. A Sciton alum, Deguara earned her PhD from Vanderbilt University in Biochemistry and has an extensive background i
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Hyperhidrosis May Up Risk for Anxiety, Depression and ADDhttps://practicaldermatology.com/news/hyperhidrosis-may-up-risk-for-anxiety-depression-and-add/2459877/Individuals with hyperhidrosis are more to have anxiety, depression and attention deficit disorder, according to new research presented at the American Academy of Dermatology’s (AAD) 2019 Annual Meeting in Washington. Of the 500 hyperhidrosis patients involved in the study, 13.8 p
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Associat
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- Hoth Therapeutics Names Dr. Adam Friedman to Scientific Advisory Boardhttps://practicaldermatology.com/news/hoth-therapeutics-names-dr-adam-friedman-to-scientific-advisory-board/2459887/Hoth Therapeutics, Inc. has named Adam Friedman, MD to the Company's Scientific Advisory Board. Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Scientific Adviso